Sign In
Buy ELAB
$1.81
+0.130 (+7.74%)
At Close: Jun 03, 2026
PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture
08:31am, Thursday, 16'th Jan 2025
NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced t
PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
09:30am, Wednesday, 15'th Jan 2025
PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants. Northstrive Biosciences Inc., formerly Elevai Bioscienc
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
03:55pm, Thursday, 02'nd Jan 2025
Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWS
Carmell and PMGC Holdings Inc Announce Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
07:30pm, Friday, 20'th Dec 2024
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) an
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
07:30am, Friday, 20'th Dec 2024
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) an
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
07:30am, Friday, 06'th Dec 2024
Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System. Root Renewal System Features Exclusive Technologies and Science-Driven Formulations.
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
06:23pm, Friday, 22'nd Nov 2024
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
05:00pm, Friday, 22'nd Nov 2024
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn
CORRECTION - Elevai Labs Inc.
02:35pm, Thursday, 14'th Nov 2024
NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results ar
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
09:08am, Thursday, 14'th Nov 2024
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakth
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
05:45pm, Monday, 04'th Nov 2024
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended an
NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Dr
